Author

P. East

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 2

Frequent Co-Authors

J. Downward· 4 shared C. Moore· 3 shared E. Mugarza· 3 shared J. Boumelha· 3 shared M. Molina-Arcas· 3 shared S. de Carne Trecesson· 3 shared S. Rana· 3 shared C. Swanton· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. Downward

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Cell Cycle Regulation has Shaped Budding Yeast Replication Origin Structure and Function

J. Diffley, C. T. Lim, T. C. Miller, K. W. Tan, s. Talele, A. Early, P. East, H. Sanchez, N. H. Dekker, A. Costa

The paper shows that CDK regulation influences MCM helicase loading at yeast origins, revealing how cell cycle control has shaped origin structure and function.

bioRxiv · Jan 10, 2024Biochemistry

CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer

J. Boumelha, A. de Castro, N. Bah, H. Cha, S. de Carne Trecesson, S. Rana, P. Anastasiou, E. Mugarza, C. Moore, R. Goldstone, P. East, K. Litchfield, S.-H. Lee, M. Molina-Arcas, J. Downward

The paper identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer through CRISPR/Cas9 screening and shows targeting COX-2 enhances immune checkpoint blockade efficacy.

bioRxiv · Apr 13, 2023Cancer Biology

A heterotrimeric complex of Toxoplasma proteins promotes parasite survival in interferon gamma stimulated human cells

E. Lockyer, F. Torelli, S. Butterworth, O.-R. Song, S. Howell, A. Weston, P. East, M. Treeck

The paper identifies a heterotrimeric complex of Toxoplasma proteins that enhances parasite survival in IFNγ-activated human cells.

bioRxiv · Dec 8, 2022 · PreprintMicrobiology

Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. L. Sopena, P. East, R. Ambler, P. Anastasiou, P. R. Clavijo, K. Valand, M. Cole, M. Molina-Arcas, J. Downward

KRASG12C inhibition enhances anti-tumour immunity in immunogenic lung cancers by upregulating interferon signaling through Myc repression, but only synergizes with immune checkpoint blockade in highly immunogenic models.

bioRxiv · Oct 18, 2021Cancer Biology

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma

P. East, G. Kelly, D. Biswas, M. Marani, D. C. Hancock, T. Creasy, K. Sachsenmeier, C. Swanton, S. de Carne Trecesson, J. Downward

This study develops a transcriptional signature to measure RAS pathway activity in lung adenocarcinoma, showing it better predicts chemotherapy response and prognosis than KRAS mutation status.

bioRxiv · Apr 2, 2021Cancer Biology

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

J. Boumelha, S. de Carne Trecesson, E. Law, P. Romero-Clavijo, M. Coelho, K. Ng, E. Mugarza, C. Moore, S. Rana, D. Caswell, M. Murillo, D. Hancock, P. Argyris, W. Brown, C. Durfee, , J. Downward

This paper develops an immunogenic mouse model of KRAS-mutant lung cancer that responds to immunotherapy and reveals immune responses target endogenous retroviral antigens rather than neoantigens.

bioRxiv · Dec 22, 2020Cancer Biology